Setpoint Medical enrolls first patients in multiple sclerosis neuroimmune modulation pilot study
Summary
Setpoint Medical announced first patient enrollment in a pilot study evaluating neuroimmune modulation for multiple sclerosis — extending the cholinergic anti-inflammatory pathway approach beyond rheumatoid arthritis (pivotal trial published in Nature 2025) into a second major autoimmune indication. The MS study evaluates Setpoint's implantable vagus nerve stimulator for modulating the neuroinflammatory component of MS, which drives progression independent of the relapsing-remitting attacks targeted by existing disease-modifying therapies.
Why it matters
Multiple sclerosis is Setpoint's most strategically significant indication expansion — MS affects 2.8 million people globally and the neuroinflammatory progressive phase has no effective treatments. A bioelectronic device modulating neuroinflammation in MS without immunosuppression would address the treatment-resistant progressive population that represents MS's greatest unmet need.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial